CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts

Warts Clinical Trial

Official title:

A Multicenter, Prospective, Randomized, Comparison IDE Study Between the Pulse Biosciences CellFX System and Cryosurgery for the Treatment of Cutaneous Non-Genital Common Warts

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04738734
• Other study ID #: NP-WC-015
• Status: Completed
• Phase: N/A
• Start date: February 16, 2021
• Est. completion date: September 25, 2022

Study information

• Verified date: November 2023
• Source: Pulse Biosciences, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This prospective, multicenter, single-blinded, randomized comparison study is designed to compare the safety and effectiveness of the CellFX System to Cryosurgery for the clearance of cutaneous non-genital common warts on all areas of the body excluding the scalp, nose, within the orbital region of the face, plantar or periungual area in healthy adult subjects.

Description:

The study will enroll healthy adult subjects with a minimum of two cutaneous non-genital warts, excluding the face, with each wart lesion not exceeding 10 x 10mm. Macrophotography of all study warts will be captured along with a blinded site Investigator to characterize wart healing, wart clearance and wart reduction. All subjects will be followed at 7, 30, 60, and 90-days following the last CellFX or Cryosurgical Procedure. All wart lesions are eligible for up to a total of 3 treatments over the course of the study. Adverse events will be documented.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: September 25, 2022
• Est. primary completion date: December 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subjects must be at least 21 and not older than 80 years of age

• Subject has a Fitzpatrick Skin Type I, II, III or IV.

• Subject gives voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.

• Subject must comply with study procedures including all follow-up visits.

• Subject is willing to have warts treated in a single treatment session and understands that their warts may undergo multiple treatment sessions at subsequent visits.

• Subject must have a minimum of 2 warts and up to 8 warts to be treated.

• Subject with a clinical diagnosis of common warts located on hands and fingers or other body areas that are not located on the scalp, nose, within the orbital region of the face, plantar, genital or periungual area.

• For study purposes, the warts must be no greater than 3 mm in height and must not exceed 10mm x 10mm at their largest dimension.

• Each wart must appear alone and discrete and not appear in clusters.

• Each wart must have been present for at least 4 weeks.

• Subject consents to have photographs taken of the warts.

• Subject agrees to refrain from using all other wart removal products or treatments (e.g.

topical medication including over-the-counter medications) during the study period.

Exclusion Criteria:

• Subject with more than 8 visible warts in total anywhere on the body.

• Subject has flat, periungual, subungual, genital, anal, mosaic, plantar or filiform warts.

• Subject has an implantable electronic medical device.(i.e., pacemaker, implantable cardioverter defibrillator)

• Subject has an active infection or history of infection in designated test area within 90 days prior to first treatment.

• Subject is taking antihistamines, including those used for gastric symptoms.

• Subject is prone to Koebnerization or has any of the following conditions (e.g., psoriasis, vitiligo, lichen planus, or an autoimmune disorder of the skin)

• Subject is not willing or able to sign the Informed Consent.

• Subject is known to be immune compromised.

• Subject has allergies to Lidocaine or Lidocaine-like products.

• Subject is a member of a vulnerable population including individuals employed by the

• Sponsor, clinic site, or entity associated with the conduct of the study.

• Have any condition or situation which, in the Investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study.

• Use of any other investigational drug, therapy, or device within the past 30 days of enrollment or concurrent participation in another research study.

• Subject was previously treated with CellFX for warts.

Related Conditions & MeSH terms

• Verruca
• Warts
• Warts Hand

Intervention

Device:
• CellFX System Device
The CellFX System utilizes non-thermal, localized delivery of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.
• Cryosurgery Liquid Nitrogen Sprayer
Cryosurgery will be standardized across all investigational sites using the Brymill Cry-Ac spray canister with standard cryoprobe.

Locations

Country	Name	City	State
United States	Moy-Fincher-Chipps Dermatology	Beverly Hills	California
United States	Dermatology & Laser Center of Charleston	Charleston	South Carolina
United States	Dermatology, Laser & Vein Specialists of the Carolinas	Charlotte	North Carolina
United States	Palm Harbor Dermatology	Clearwater	Florida
United States	AboutSkin Dermatology and DermSurgery	Greenwood Village	Colorado
United States	Austin Institute for Clinical Research, Inc.	Houston	Texas
United States	Oak Dermatology	Joliet	Illinois
United States	Juva Skin & Laser Center	New York	New York
United States	Austin Institute for Clinical Research, Inc.	Pflugerville	Texas
United States	Investigate MD	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Pulse Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Warts Resolved	The primary effectiveness endpoint is the percentage of warts resolved or cleared as assessed "live" by the blinded site investigator at 30 days after the last treatment with CellFX or Cryosurgical Procedure.	30 days following the last CellFX or Cryosurgical Procedure up to a maximum of 3 months
Primary	Percentage of Warts Treated With Skin Textural Changes	The safety endpoint is the percentage of warts with skin textural changes where the wart was originally treated and showed textual changes of the surrounding skin where the wart was treated and included; scabbing, swelling, crusting, blister, or ulceration when assessed by the blinded site investigator.	30 days from the last CellFX or Cryosurgical Procedure up to a maximum of 3 months
Primary	Presence of Pigmentary and Scarring Skin Changes	The skin change safety event is defined as the presence of hyperpigmentation, hypopigmentation, or scarring as assessed by the blinded site investigator.	90 days from the last CellFX or Cryosurgical Procedure up to a maximum of 6 months